References for 2023 kumamoto university research plan, KI-SEOK LEE


The figure are created with BioRender website


[1] Johannes M. Aerts et al. "Elevated globotriaosylsphingosine is a hallmark of Fabry disease" PNAS 105 (8) 2812-2817 (2008) https://doi.org/10.1073/pnas.0712309105

[2] Atul Mehta et al. "Fabry Disease" Oxford PharmaGenesis; (2006) https://www.ncbi.nlm.nih.gov/books/NBK11586/

[3] Germain DP, et al. "Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease" J Med Genet  5 2:353–358 (2015) http://dx.doi.org/10.1136/jmedgenet-2014-102797 

[4] RxList “ Fabrazyme “ https://www.rxlist.com/fabrazyme-drug.htm#clinpharm

[5] Shin Yoshimoto, et al. "Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome" Nature 499, pages 97–101 (2013) https://doi.org/10.1038/nature12347

[6] Rui-Ming Liu "Aging, Cellular Senescence, and Alzheimer’s Disease" Int. J. Mol. Sci. 23(4), 1989 (2022) https://doi.org/10.3390/ijms23041989

[7] Han, Y et al. "Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics" Exp Mol Med 55, 1–12 (2023) https://doi.org/10.1038/s12276-022-00906-w

[8] Alessia Lo Curto et al. "Can Be miR-126-3p a Biomarker of Premature Aging? An Ex Vivo and In Vitro Study in Fabry Disease" Cells, 10(2), 356 (2021) https://doi.org/10.3390/cells10020356

[9] Hyo-Sang Do et al. "Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells" eBioMedicine  VOLUME 52, 102633 (2020) https://doi.org/10.1016/j.ebiom.2020.102633

[10] Paula Rozenfeld et al. "Contribution of inflammatory pathways to Fabry disease pathogenesis" Mol. Genet. Metab. Volume 122, Issue 3 (2017) https://doi.org/10.1016/j.ymgme.2017.09.004

[11] Marc Chévrier et al. "Autophagosome maturation is impaired in Fabry disease" Autophagy 6(5):589-99 (2010) https://doi.org/10.4161/auto.6.5.11943

